ArticleSAGE open medicine2021
Clinical complications in patients with primary and recurrent
Article in SAGE open medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Biological Mechanisms of Polyphenols againstInfectious disorders drug targets · 2025Pooled it
- Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis.Advances in therapy · 2023Pooled it
- Temporal windowing of recurrent sinusitis improves EHR-based immunodeficiency classification.Journal of human immunity · 2026Article
- Risk factors for further recurrences of Clostridioides difficile infection at the first and second recurrence: a retrospective cohort.BMC infectious diseases · 2025Article
- Article
- Article
- Defining FulminantOpen forum infectious diseases · 2025Article
- Protection against Clostridioides difficile disease by a naturally avirulent strain.Cell host & microbe · 2025Article
- The 3 Ds: Depression, Dysbiosis, and Clostridiodes difficile.Advances in therapy · 2024Review
- Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Impact of an Intervention Program onOpen forum infectious diseases · 2024Article
- Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: the RECUR Germany study.BMC infectious diseases · 2024Article
- Protection againstbioRxiv : the preprint server for biology · 2024Article
- Environmental and Nutritional Parameters Modulating Genetic Expression for Virulence Factors ofAntibiotics (Basel, Switzerland) · 2024Review
- Microbiota-Based Therapeutics as New Standard-of-Care Treatment for RecurrentVisceral medicine · 2024Review
- Epidemiological and clinical burden of Clostridioides difficile infections and recurrences between 2015 - 2019: the RECUR Germany study.BMC infectious diseases · 2024Observational
- Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection.Infectious diseases and therapy · 2024Article
- Microbiota-Based Live Biotherapeutic Products forInfection and drug resistance · 2024Review
- Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With RecurrentOpen forum infectious diseases · 2023Article
- Increased Incidence and Risk of Septicemia and Urinary Tract Infection AfterOpen forum infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objective
methodsA retrospective analysis of commercial claims data from the IQVIA PharMetrics Plus™ database was conducted for patients aged 18-64 years with an index
resultsIn total, 46,571 patients with index
conclusionsReduction in recurrent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.